Prior Art Litigation Search in Ghent.

A prior art search Ghent litigation counsel can rely on has to read like a molecular biologist and a chemical engineer at once — because around the Leie the patents that get asserted claim genes, plant traits, fermentation processes and green-chemistry compositions, not consumer gadgets. Ghent is the beating heart of European plant and industrial biotechnology: it was here in the 1970s that Marc Van Montagu and Jeff Schell at Ghent University worked out how to use the Agrobacterium Ti-plasmid to stably insert genes into plants, the discovery that launched the entire transgenic-crop industry. That legacy now lives in VIB’s Center for Plant Systems Biology, the agri-biotech cluster on the former CropDesign (BASF) site, and the Bio Base Europe Pilot Plant scaling up fermentation and biorefinery processes in the North Sea Port. When a patent covering that kind of technology is enforced in Belgium, the validity fight is not heard in Ghent at all — it goes to Brussels, before the Enterprise Court that holds exclusive national jurisdiction, or to the Belgian local division of the Unified Patent Court. PerspireIP builds the invalidity-grade searches the accused Ghent parties rely on.

Ghent’s biotech and agrifood cluster: where the patent fights start

Ghent is one of the densest life-science hubs in Europe, and its patents show it. The city is home to the VIB (Vlaams Instituut voor Biotechnologie) Center for Plant Systems Biology, run jointly with Ghent University, and to Tech Lane Ghent Science Park at Ardoyen, where academic spin-offs and multinationals cluster around a single research corridor. The plant-biotech pedigree is unmatched: in the 1970s and 1980s Marc Van Montagu and Jeff Schell pioneered Agrobacterium-mediated gene transfer using the Ti-plasmid, the foundational technique behind virtually every genetically improved crop on the market. That work seeded a cluster that companies such as BASF (through the former CropDesign) and Bayer/Syngenta plant-science operations have drawn on ever since.

The cluster is not only about crops. In the North Sea Port the Bio Base Europe Pilot Plant scales up biomass pretreatment, biocatalysis, fermentation, gas fermentation and green chemistry, turning renewable feedstocks into biochemicals, biomaterials and biofuels. Ghent’s agrifood tradition, its textiles and new-materials heritage, and the chemical activity around the port round out a technology base that reads on gene sequences, plant traits, microbial strains, fermentation and downstream-processing methods, enzyme and formulation chemistry, and biobased materials.

That profile shapes the patent litigation. The rights asserted around Ghent are biotech, agrifood and chemistry patents, and their claims are broad, functional and often written around biological subject-matter. When a competitor or a licensor asserts one against a Ghent spin-off, a plant-science multinational or a fermentation start-up, the accused party is rarely fighting over a device — it is fighting over whether a claimed sequence, trait or process was already known to the field. That is precisely the terrain a rigorous prior-art search has to master.

Where a prior art search Ghent case is heard

Ghent generates the disputes, but it does not try them. Since the 2014–2015 reform of Belgian patent jurisdiction, the Enterprise Court of Brussels (Ondernemingsrechtbank Brussel / Tribunal de l’entreprise de Bruxelles) has held exclusive national jurisdiction over Belgian patent infringement and validity. Wherever the parties sit — Ghent, Antwerp or Leuven — an action on a Belgian patent or the Belgian part of a European patent is filed in Brussels, with appeals to the Brussels Court of Appeal. Belgium does not bifurcate, so infringement and validity are decided together in one proceeding, and an accused party typically answers with a nullity counterclaim that puts the asserted claim’s validity directly in play.

There is a second forum. Belgium is a full member of the Unified Patent Court and hosts a Brussels Local Division, running proceedings in Dutch, French, German or English. The UPC hears unitary patents and European patents that have not been opted out, and a revocation counterclaim there can knock the patent out across every participating state at once — a far larger prize, and a far larger exposure, than a Belgian-only nullity ruling. For any European patent still inside the nine-month EPO opposition window, a central attack at the European Patent Office is a third route that reaches all validations together.

So a prior art search Ghent counsel commission has to be built for the forum that will actually decide the case. The evidentiary standard, the language, and the reach of the ruling differ between a Brussels Enterprise Court nullity, a UPC revocation and an EPO opposition, and we scope every search to the venue in play.

• Enterprise Court of Brussels — exclusive first-instance forum for Belgian patent infringement and nullity
• Brussels Court of Appeal — the appellate route from that court
• UPC Brussels Local Division — a parallel forum for unitary and non-opted-out European patents, with pan-European revocation reach
• EPO opposition — a central revocation filed within nine months of grant, reaching every validation at once

UPC or the national court: the forum choice for a Ghent European patent

Most valuable technology around Ghent is protected by European patents, and for those the choice of forum is now a live strategic decision. The Unified Patent Court opened on 1 June 2023, and for a transitional period — seven years, expiring on 1 June 2030 unless extended for up to a further seven — a classical European patent can still be litigated either at the UPC or before the national courts. During that window a proprietor may opt a classical European patent out of the UPC under Article 83 UPCA, keeping any dispute in the Brussels Enterprise Court; a unitary patent, by contrast, can never be opted out and lives exclusively at the UPC.

For an accused Ghent party the practical consequence is that the same asserted right may be attackable in more than one place, and the best attack is not always the obvious one. A UPC central revocation or counterclaim reaches Belgium plus every other participating state, which is powerful when the product is sold across Europe — but it also concentrates the risk in a single ruling. A national nullity keeps the fight to the Belgian right; an EPO opposition, where the patent is young enough, reaches all validations at the lowest cost. Each route rewards a different prior-art package, and the search has to be assembled with the forum decision already in view.

• Unitary patent — UPC only, no opt-out; revocation there is pan-European
• Classical European patent (not opted out) — UPC or Belgian national court during the transitional period
• Classical European patent (opted out) — Brussels Enterprise Court, for the life of the patent
• Belgian national patent — Brussels Enterprise Court, exclusively

Why a prior art search Ghent nullity turns on the EPO record

Belgium’s national grant procedure makes prior art unusually decisive. The Belgian Office for Intellectual Property (OPRI/DIE), within the FPS Economy, grants Belgian national patents through a registration system with no substantive examination. The applicant must request a novelty search within thirteen months of filing; that search and the written opinion are carried out by the European Patent Office on the office’s behalf, but they do not bind the grant. A Belgian patent is granted roughly eighteen months after filing even where the EPO opinion is negative — so a national patent can reach grant without any patentability check ever having gated it.

That is why a Ghent nullity so often succeeds on art the granting authority never weighed. The grounds are set out in Book XI of the Code of Economic Law (Article XI.57) and track the European Patent Convention: the subject-matter is not patentable or lacks novelty, inventive step or industrial applicability; the specification is insufficient to let a skilled person work the invention; the claims contain added matter beyond the application as filed; or the proprietor is not entitled to the patent. Novelty and inventive step are the prior-art grounds, and in biotech and chemistry they carry most nullity attacks.

For inventive step the Brussels court and the UPC both apply the EPO’s problem-and-solution approach — identify the closest prior art, define the objective technical problem, and ask whether the claimed solution was obvious. In the life sciences that framework rewards a searcher who can produce a genuine closest reference, because obviousness here often turns on whether a sequence, a promoter, a strain modification or a formulation range was a routine step for the skilled person. A well-scoped invalidity search regularly surfaces exactly the disclosure the EPO opinion missed.

• Lack of novelty — a single earlier disclosure anticipating every claim element
• Lack of inventive step — obvious over the closest art under the problem-solution approach
• Insufficiency — the specification does not enable the skilled person to reproduce the invention
• Added matter — granted claims extending beyond the application as filed
• Lack of entitlement — the proprietor is not the person entitled to the patent

What Ghent biotech, agrifood and materials patents actually claim

The subject-matter around Ghent is what makes its invalidity work distinctive. Plant-biotech patents claim gene and DNA sequences, promoters and regulatory elements, transformation methods, and engineered traits such as herbicide tolerance, pest resistance, yield or stress tolerance. Agrifood and industrial-biotech patents claim microbial strains, enzymes, fermentation and gas-fermentation processes, downstream separation and purification steps, and biobased chemicals and materials. Green-chemistry filings from the North Sea Port cluster read on catalytic and biocatalytic routes, feedstock conversion and formulation compositions. Even the city’s textiles and new-materials heritage surfaces in coating, fibre and composite claims.

Each of those claim types fails on a different kind of art. A sequence claim can be anticipated by a deposited sequence in a public database; a trait claim by an earlier field trial or breeding record; a fermentation-process claim by a decades-old microbiology paper or an engineering handbook; a formulation claim by a supplier datasheet or a prior product. A prior art search Ghent defendants can build a nullity case on therefore cannot be a patent-database sweep alone — it has to reach the scientific and commercial record where life-science disclosure actually lives.

It also has to respect biotech’s peculiar disclosure rules. In this field a single enabling publication — a paper reporting a sequence and its function, a poster describing a strain, a thesis characterising an enzyme — can anticipate a later claim, and the enablement bar for both the prior art and the patent itself is high. We build searches that test not just whether a document mentions the subject-matter, but whether it enabled the skilled person to make and use it before the priority date.

Where the decisive biotech prior art lives — and how we find it

Biotech and agrifood invalidity is unusually dependent on the record outside the patent system, and Ghent cases live there. The disclosure that sinks a life-science claim is often a journal article, a conference abstract or poster, a doctoral thesis, a deposited sequence, a field-trial or regulatory record, or an older patent family in a different jurisdiction — none of which a searcher working only patent databases is likely to surface. Molecular biology and plant science have published their fundamentals openly for decades, so the closest art is frequently a paper or a database entry, not a patent.

Sequence prior art needs its own tooling. A nucleotide or amino-acid claim is tested against public sequence repositories — GenBank, the EMBL-EBI/ENA databases, UniProt and the sequence listings inside patent families — using alignment searches rather than keywords, because a sequence disclosed under a different name or annotation is still anticipatory. We combine sequence retrieval with deep non-patent literature searching and with WIPO PATENTSCOPE and EPO patent-family analysis, so an assertion is checked against every register in which the relevant disclosure could sit.

Public-availability dating is where these cases are ultimately won or lost. A conference poster, a preprint, an online supplementary dataset, a thesis release or a database deposit can be devastating prior art — but only if its public-availability date is proven to precede the priority date of the asserted claim. In the life sciences the strongest reference is often the hardest to date, so we evidence when each document or record became public with the same rigour we apply to a granted patent, down to the day where it matters.

• Sequence databases — GenBank, EMBL-EBI/ENA, UniProt and patent sequence listings, searched by alignment
• Scientific literature — plant-science, microbiology, enzymology and chemical-engineering journals, plus conference posters and abstracts
• Theses and field records — doctoral dissertations, breeding and field-trial data, and regulatory or safety filings
• Patent families — earlier applications and grants worldwide via EPO Espacenet and WIPO PATENTSCOPE, dated to publication

How PerspireIP builds a Ghent invalidity search

Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the priority date that actually governs each one, and search against that date rather than the filing date printed on the cover. For biotech and chemistry assertions we pair patent searching with sequence-database alignment and deep non-patent retrieval — journals, theses, posters, field-trial and regulatory records, standards and product documentation — and we date every reference precisely, because in the life sciences public availability is contested as often as content.

• Claim charting mapped to novelty and inventive step under Book XI of the Code of Economic Law and the EPC
• Sequence-based searching for gene, DNA and protein claims across public repositories and patent listings
• Deep non-patent retrieval across plant-science, microbiology, enzymology and chemical-engineering sources, in multiple languages
• Public-availability dating for every reference — papers, posters, theses, database deposits and online disclosures alike
• Prior art scoped to your forum — a Brussels Enterprise Court nullity, a UPC revocation counterclaim, or the nine-month EPO opposition window

We work alongside your Belgian and European counsel as a specialist search partner, deliver to Enterprise Court, UPC and EPO deadlines, and keep every engagement confidential. Whether you are a Ghent University spin-off facing a licensor’s assertion, a plant-science or fermentation company challenging a competitor’s patent, or litigation counsel preparing a nullity counterclaim, a rigorous prior art search Ghent teams can build the defence on is what turns exposure into leverage. Send us the patent number and your key dates, and we will scope the work within one business day.

IP Landscape & Resources in Ghent

Key intellectual-property authorities and venues relevant to Ghent:

• FPS Economy – Intellectual Property (OPRI/DIE) — the Belgian Office for Intellectual Property within the FPS Economy, which grants Belgian national patents through a registration system with no substantive examination
• Unified Patent Court — the UPC, whose Brussels Local Division and central divisions can revoke a unitary or non-opted-out European patent across participating states
• European Patent Office (EPO) — carries out the novelty search behind a Belgian national patent, grants European patents validated in Belgium, and runs post-grant opposition within nine months of grant
• WIPO PATENTSCOPE — WIPO's global patent database, used to retrieve and date international patent families and sequence listings when building invalidity art

Request a Prior Art Search in Ghent

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions